TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39727027
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (antiplatelet therapy and stroke risk factor control)
Study: 39727053
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg single dose)
Study: 39727283
Drug: Oxylanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxylanthanum carbonate 500 mg TID
Study: 39727283
Drug: Oxylanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxylanthanum carbonate 1000 mg TID
Study: 39727283
Drug: Oxylanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxylanthanum carbonate 1500 mg TID
Study: 39727283
Drug: Oxylanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxylanthanum carbonate 2000 mg TID
Study: 39727476
Drug: Silver Diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Diamine Fluoride Gel
Study: 39729067
Drug: Short-term menopausal
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term menopausal hormone therapy (mHT)
Study: 39729347
Drug: Glucagon-Like Peptide-1
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-Like Peptide-1 Receptor Agonists
Study: 39729347
Drug: Sodium-Glucose Cotransporter
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-Glucose Cotransporter 2 Inhibitors
Study: 39729347
Drug: Dipeptidyl Peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl Peptidase-4 Inhibitors
Study: 39729440
Drug: Faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal microbiota transplantation via rectal tube, using a preparation mixed from 7 thawed aliquots (50 mL) from fresh stool of 7 healthy unrelated donors.
Study: 39729440
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment based on oral diosmectite.
Study: 39729440
Drug: Faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal microbiota transplantation via rectal tube.
Study: 39729499
Drug: Ruxolitinib (RUX)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (RUX) as first-line therapy
Study: 39729499
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) as first-line therapy
Study: 39730000
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist)
Study: 39731298
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) plus methylene blue tracing for sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC)
Study: 39731908
Drug: Adoptive Treg
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive Treg therapy
Study: 39731909
Drug: Hydroxychloroquine (HCQ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ; 600 mg, bid) plus palbociclib (200 mg, qd)
Study: 39732438
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of inulin (20g in 62.5mL every 45 minutes over 6 hours)
Study: 39732483
Drug: Functional remission
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional remission group (patients who achieved functional remission after antipsychotic discontinuation)
Study: 39732483
Drug: Functional non-remission
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional non-remission group (patients who did not achieve functional remission after antipsychotic discontinuation)
Study: 39732649
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly self-collected oral swabs (OS)
Study: 39732649
Drug: Once-weekly self-collected
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly self-collected oral-nasal swab (ONS)
Study: 39732696
Drug: UFH/LMWH +
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH/LMWH + 20 mg rtPA/6 h intravenously
Study: 39732696
Drug: UFH +
Normalized name: Unfractionated Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UFH + 20 mg rtPA/6 h via USAT
Study: 39732701
Drug: mSoCIAL (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSoCIAL (modified Social Cognition Individualized Activity Lab), 10 weekly sessions
Study: 39732703
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AYP-101
Study: 39732703
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg AYP-101
Study: 39733282
Drug: Bilateral normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral normal saline pudendal injections
Study: 39733282
Drug: No pudendal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pudendal injection
Study: 39733294
Drug: p-DCR-FFP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-DCR-FFP (250 mL)
Study: 39734047
Drug: Sprifermin 100 μg
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin 100 μg every 6 months (Q6M)
Study: 39734047
Drug: Sprifermin 100 μg
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin 100 μg every 12 months (Q12M)
Study: 39734047
Drug: Sprifermin 30 μg
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin 30 μg every 6 months (Q6M)
Study: 39734047
Drug: Sprifermin 30 μg
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin 30 μg every 12 months (Q12M)
Study: 39734708
Drug: CEA-directed CAR
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA-directed CAR T therapy
Study: 39736329
Drug: 1.5 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/kg/day
Study: 39736329
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day
Study: 39736329
Drug: 1.1 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 g/kg/day
Study: 39736452
Drug: Immunochemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy plus radiotherapy (ICR) with definitive dose RT to primary tumor
Study: 39736544
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (PRT)
Study: 39736787
Drug: IBI110 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 monotherapy (0.01/0.1/0.3/1/3/10/20 mg/kg Q3W)
Study: 39736787
Drug: IBI110 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 plus sintilimab (0.3/0.7/1.5/3/5/8/10 mg/kg Q3W + sintilimab 200 mg Q3W)
Study: 39736787
Drug: IBI110 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in sqNSCLC
Study: 39736787
Drug: IBI110 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in GC
Study: 39737219
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg IV) + Tremelimumab (75 mg IV) on Day 1 q4 weeks for 4 cycles followed by Durvalumab q4 weeks until disease progression
Study: 39737328
Drug: Live group
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live group music therapy session + standard care
Study: 39737640
Drug: Tofacitinib (JAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (JAK inhibitor) for 16 weeks
Study: 39737816
Drug: Low-dose emicizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose emicizumab prophylaxis (2.0-2.5 mg/kg every fortnight for two loading doses, then every 4 weeks) for 8 months
Study: 39737816
Drug: Low-dose emicizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose emicizumab prophylaxis
Study: 39739628
Drug: RO5459072 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5459072 (100 mg b.i.d., 200 mg daily)
Study: 39739679
Drug: DILEU (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DILEU (2 grams daily)
Study: 39739762
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g twice a day for 14 days)
Study: 39739976
Drug: Upamostat (LH011)
Normalized name: Upamostat
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upamostat (LH011) at doses of 100, 200, 400, or 600 mg daily combined with gemcitabine (1000 mg/m2)
Study: 39739976
Drug: Upamostat (LH011)
Normalized name: Upamostat
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upamostat (LH011) at doses of 100 to 600 mg
Study: 39739990
Drug: LOW dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW dose prolonged-release tacrolimus (TAC) with other antihypertensive therapy (OAHT)
Study: 39739990
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose prolonged-release tacrolimus (TAC) with or without ACEi/ARB
Study: 39739990
Drug: LOW dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW dose prolonged-release tacrolimus (TAC) with renin-angiotensin system (RAS) blockade
Study: 39739990
Drug: LOW dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW dose prolonged-release tacrolimus (TAC) without RAS blockade
Study: 39740215
Drug: Complete Lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Lifestyle Medicine Intervention Program-Ontario (CLIP-ON) consisting of 22 weeks of weekly group sessions and monthly individual consultations with physicians, health coaches, kinesiologists, and registered dieticians.
Study: 39740313
Drug: Cabozantinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib at 60 mg/day (recommended dose)
Study: 39740941
Drug: WJ-UC-MSC solution
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: WJ-UC-MSC solution
Study: 39740945
Drug: Creative Arts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative Arts and Psychomotor Therapies (CAPTs) intervention
Study: 39740951
Drug: PIT programme
Normalized name: Pit viper (crotalid) antivenin (equine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIT programme (pharmacist reconciliation of medications and structured handoff)
Study: 39741233
Drug: CKI combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKI combined with first-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Study: 39741233
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Study: 39742013
Drug: Stress Ball
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Ball intervention, details on dosage and duration not available
Study: 39742565
Drug: IGRA+ pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGRA+ pre-treatment (n=15)
Study: 39742565
Drug: IGRA+ post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IGRA+ post-treatment (n=15)
Study: 39743016
Drug: Electronic Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic Health Record (EHR) data on concurrent patients not offered InBloom or ROSE
Study: 39743172
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers (no BB)
Study: 39743436
Drug: Abatacept (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10, 20, or 25 mg/kg) administered intravenously on Days 1, 5±2, and 14±2
Study: 39743436
Drug: Abatacept (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10, 20, or 25 mg/kg) with concomitant ruxolitinib and corticosteroids
Study: 39743478
Drug: First-line oxaliplatin-based
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First-line oxaliplatin-based chemotherapy
Study: 39744745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3 ml 0.1% ropivacaine with 0.3 μg ml-1 sufentanil through the Tuohy needle followed by a 15 ml loading dose over 30 seconds
Study: 39744745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the same ropivacaine/sufentanil mixture through a single end-hole epidural catheter
Study: 39744861
Drug: Tenecteplase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.25 mg/kg intravenously)
Study: 39744861
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (including 23% receiving intravenous tissue-type plasminogen activator)
Study: 39744921
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 μg orally twice daily for 48 weeks
Study: 39745099
Drug: Physical assessments
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical assessments after 6 months of cancer treatment
Study: 39745682
Drug: Nontransplant salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontransplant salvage therapy (radiotherapy) for low-risk patients (n=41)
Study: 39745701
Drug: Parent-targeted oral
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-targeted oral health text (OHT) messages
Study: 39745702
Drug: Standard egg-based
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard egg-based quadrivalent inactivated influenza vaccine (IIV4)
Study: 39746515
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) combined with mometasone furoate nasal spray (MFNS)
Study: 39746964
Drug: Liposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal irinotecan (HE072) at dose levels of 50, 70, and 90 mg/m²
Study: 39747856
Drug: GT103 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT103 (0.3 mg/kg)
Study: 39747856
Drug: GT103 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT103 (1 mg/kg)
Study: 39747856
Drug: GT103 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT103 (10 mg/kg every 3 weeks)
Study: 39747856
Drug: GT103 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT103 (various doses)
Study: 39747998
Drug: Delandistrogene moxeparvovec
Normalized name: Delandistrogene moxeparvovec
DrugBank: Delandistrogene moxeparvovec (DB16802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delandistrogene moxeparvovec micro-dystrophin gene therapy
Study: 39748396
Drug: Antenatal breastmilk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal breastmilk expression (aBME) for 10 minutes, 2 times daily from week 34 until birth.
Study: 39748428
Drug: CD33-targeted CAR-NK
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD33-targeted CAR-NK cell therapy
Study: 39748491
Drug: Liposomal mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal mitoxantrone (Lipo-MIT) monotherapy
Study: 39749555
Drug: PNF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNF with corticosteroid injection
Study: 39749555
Drug: PNF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNF with saline injection
Study: 39751879
Drug: Serplulimab 3
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab 3 mg/kg plus HLX04 10 mg/kg (first-line)
Study: 39751937
Drug: PD-1 blockade-activated
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 blockade-activated neoantigen specific cellular therapy (aNASCT)
Study: 39751962
Drug: Neoadjuvant darolutamide
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant darolutamide plus androgen deprivation therapy (ADT) for six months
Study: 39751970
Drug: Esketamine-butorphanol group
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine-butorphanol group (Group BK) receiving esketamine 1.5 mg/kg and butorphanol 0.15 mg/kg, azasetron 20 mg.
Study: 39751970
Drug: Butorphanol group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol group (Group B) receiving butorphanol 0.15 mg/kg and azasetron 20 mg (normal saline as control).
Study: 39753296
Drug: jaktinib 100 mg
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: jaktinib 100 mg two times per day
Study: 39753296
Drug: jaktinib 75 mg
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: jaktinib 75 mg two times per day
Study: 39753485
Drug: Sacituzumab govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan-hziy (10 mg/kg weekly on days 1 and 8 of 21-day cycles)
Study: 39753970
Drug: BNT221, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, tested in a 3 + 3 dose-finding study with two dose levels (DLs).
Study: 39754114
Drug: hPH injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPH injection
Study: 39754114
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injection
Study: 39754489
Drug: Intra-arterial alteplase
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg)
Study: 39754976
Drug: Triptorelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin plus letrozole (L)
Study: 39755576
Drug: Antenatal multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal multiple micronutrient supplements (MMS) at varying doses up to ~75% of the tolerable upper intake level (UL)
Study: 39755598
Drug: TCD pulsatility
Normalized name: TCDO
DrugBank: Tetrachlorodecaoxide (DB05389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCD pulsatility index guided norepinephrine titration
Study: 39755925
Drug: Lorecivivint (LOR)
Normalized name: Lorecivivint
DrugBank: Lorecivivint (DB14883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorecivivint (LOR) 0.07 mg
Study: 39755971
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of hydrocodone with 300 mg of acetaminophen (opioid)
Study: 39755971
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen and 500 mg of acetaminophen (nonopioid)
Study: 39756444
Drug: Belzutifan 120
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily
Study: 39756446
Drug: Brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain radiotherapy combined with camrelizumab (200 mg intravenously once every 3 weeks) and platinum-doublet chemotherapy (pemetrexed 500 mg/m2)
Study: 39756446
Drug: Brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy
Study: 39756693
Drug: NVX-CoV2601 plus
Normalized name: SARS-CoV-2 (COVID-19) vaccine, protein NVX-CoV2601
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2601 plus PCV20 (combination group)
Study: 39757186
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/day) administered orally for 2 weeks followed by 1 week off in a 3-week cycle, in combination with continued use of EGFR-TKIs.
Study: 39757192
Drug: Best medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medicine treatment (control)
Study: 39757748
Drug: Iberdomide (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (1.6 mg on days 1-21), ixazomib (3 mg on days 1, 8, 15), dexamethasone (20 mg on days 1, 8, 15, 22 for cycles 1-2; 10 mg on days 1, 8, 15, 22 for cycles 3-6)
Study: 39758223
Drug: Nutraceutical supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplement (Clear Skin Formula; VitaMedica®) taken daily for 84 days
Study: 39758223
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken daily for 84 days
Study: 39758508
Drug: BP-lowering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-lowering treatment
Study: 39758508
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering treatment
Study: 39758592
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplement (SQ-LNS) provided to mothers during pregnancy and 6 months postpartum and to their children from 6 to 18 months.
Study: 39759424
Drug: Iclepertin 10
Normalized name: Iclepertin
DrugBank: Iclepertin (DB19058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclepertin 10 mg + CCT
Study: 39760061
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)